Last reviewed · How we verify

NCT06082362

Personalized Signature of Chronic Inflammation and Early Aging Predictive of the Comorbidities in Infertile Men

Status unknown Last updated 13 October 2023
What this trial tests

trial testing Collection of clinical and biological material in Male Infertility in 350 participants. Status unknown.

Timeline
21 June 2023
Primary endpoint
20 June 2024
20 June 2025

Quick facts

Lead sponsorIRCCS San Raffaele
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment350
Start date21 June 2023
Primary completion20 June 2024
Estimated completion20 June 2025
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

IRCCS San Raffaele — full company profile →

Who can join

Adults 18 to 50, male only, with Male Infertility. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the project is identify new biomarkers and/or prognostic factors in order to develop personalized strategies to prevent the onset of tumor and/or non tumor comorbidity in infertile men.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Current insights into transcriptional role(s) for the nutraceutical <i>Withania somnifera</i> in inflammation and aging.
    Saha P, Ajgaonkar S, Maniar D, Sahare S, et al · · 2024 · cited 13× · PMID 38765810 · DOI 10.3389/fnut.2024.1370951

Verify or expand the search:

Other recruiting trials for Male Infertility

Currently open trials in the same condition.

Other IRCCS San Raffaele trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06082362.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing